Histogen — Company Overview, News & Financial Data
Histogen develops regenerative medicine solutions for skincare and orthopedic regeneration using cells grown under simulated embryonic conditions.
Histogen
About
Histogen (NASDAQ:HSTO) focuses on developing regenerative medicine and therapeutics. At the heart of its operations, Histogen aims to harness the power of cells grown under simulated embryonic conditions to produce products for skin care, hair growth, and orthopedic regeneration. Through its innovative approach, Histogen is dedicated to advancing its projects in clinical trials, aiming to bring novel solutions to market that address unmet needs in medical and cosmetic fields. The objective of the company is to leverage its unique technology platform to develop treatments that can significantly improve patients' quality of life and well-being. With a commitment to research and development, Histogen is pushing the boundaries of regenerative medicine to create sustainable and effective healthcare solutions.
Snapshot
Operations
Products and/or services of Histogen
- Emricasan for treating COVID-19 by reducing lung inflammation and improving respiratory function.
- Skin care products utilizing regenerative medicine techniques to promote natural cell repair and growth.
- Hair growth products developed from proprietary regenerative medicine technology to treat hair loss.
- Wound care products designed to accelerate healing using regenerative medicine.
- Joint repair treatments employing regenerative medicine techniques to aid in the recovery of injured or worn joints.
- Aesthetic dermatology products focused on anti-aging and skin rejuvenation through regenerative medicine.
Histogen executive team
- Ms. Susan A. KnudsonPresident, CEO, CFO, COO, Chief Compliance Officer & Corporate Secretary
GET YOUR GRAFA EDGE NOW
We'll switch on a 30-day Edge trial as a welcome gift